CD274 and neoplasm: These findings suggest that CD274 may serve as an immunotherapeutic target in OS, particularly in patients with CD274 copy number amplification.[50] Additionally, Wu et al[51] identified CD274 overexpression in OS through bioinformatics and qRT-PCR analyses, which correlated with adverse prognosis, and suggested that CD274 may promote immune evasion by inhibiting the anti-tumor activity of T cells.